09061GAH4

Biomarin Pharmaceutical Inc

Could not find a ticker for this position, may be a filing error

A biotechnology company focused on rare genetic diseases, BioMarin makes enzyme-replacement and gene therapies—including VOXZOGO, the first drug approved to treat achondroplasia (dwarfism) in children—alongside treatments like VIMIZIM and NAGLAZYME used by patients with rare metabolic disorders. Founded in 1997 in Marin County, California, the company's name blends "bio" for biotechnology with "Marin," the county where it got its start. Its early founders deliberately took on rare diseases that bigger drugmakers ignored, and the company has since grown into one of the world's largest rare-disease biotechs.

CONVERTIBLEUnderlying: BMRNCUSIP: 09061GAH4HealthcareUS1 derivative reporter

0.599% Senior Subordinated Convertible Notes Due 2024

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 3 years

Insider

Bienaime Jean JacquesDirector · 30 transactions

721.3K+7.6%

as of May 2024

Granted 286.0K · Sold 143.0K

Hardy AlexanderChief Executive Officer, Director · 12 transactions

214.6K—

Granted 255.6K

Fuchs Henry JPresident, Worldwide R&D · 9 transactions

185.1K+5%

as of Sep 2024

Granted 89.5K · Sold 35.3K

Meier Richard ADirector · 6 transactions

126.9K+9.8%

Granted 20.3K

Mueller BrianEVP, Chief Financial Officer · 21 transactions

123.3K+169.2%

Granted 134.1K · Sold 5.0K

Heron Elaine JDirector · 3 transactions

101.9K+10.6%

as of Jun 2024

Granted 9.8K

Guyer Charles GregEVP, Chief Technical Officer · 27 transactions

84.1K+110.1%

Granted 133.0K · Sold 28.8K

Davis George EricEVP, Chief Legal Officer · 26 transactions

78.6K+13.1%

Granted 162.6K · Sold 107.1K

Ajer Jeffrey RobertEVP, Chief Commercial Officer · 7 transactions

66.8K+9.8%

as of May 2024

Granted 37.5K · Sold 9.0K

Friberg Gregory REVP, Chief R&D Officer · 9 transactions

51.8K—

Granted 66.4K · Sold 9.6K

Pyott David E IDirector · 1 transaction

49.8K+10.5%

as of May 2024

Granted 4.7K

Hombach Robert J.Director · 3 transactions

49.4K+61.8%

Granted 18.9K

Dere Willard HDirector · 3 transactions

46.4K+68.4%

Granted 18.9K

Hubbard CristinEVP, Chief Commercial Officer · 10 transactions

42.5K—

Granted 48.5K · Sold 273

Anderson Elizabeth MDirector · 3 transactions

41.9K+81.7%

Granted 18.9K

Slamon DennisDirector · 2 transactions

40.8K+32.5%

as of Mar 2024

Granted 10.0K

Ho MaykinDirector · 3 transactions

35.5K+113.3%

Granted 18.9K

Ramchandani Rashmi VirendraVP, Chief Accounting Officer · 2 transactions

25.6K—

Granted 25.6K

Bodem Barbara W.Director · 4 transactions

21.0K—

Granted 21.0K

Countouriotis AthenaDirector · 4 transactions

21.0K—

Granted 21.0K

Enyedy Mark JDirector · 4 transactions

21.0K—

Granted 21.0K

Walbert Timothy PDirector · 3 transactions

17.7K—

Granted 17.3K

Clark Ian TDirector · 2 transactions

14.5K—

Granted 14.5K

Burkhart ErinGVP, Chief Accounting Officer · 11 transactions

14.2K+0.6%

as of May 2025

Granted 10.7K · Sold 7.4K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Bienaime Jean JacquesDirector · 30 transactions	+7.6%	721.3Kas of May 2024	286.0K	—	143.0K
Hardy AlexanderChief Executive Officer, Director · 12 transactions	—	214.6K	255.6K	—	—
Fuchs Henry JPresident, Worldwide R&D · 9 transactions	+5%	185.1Kas of Sep 2024	89.5K	—	35.3K
Meier Richard ADirector · 6 transactions	+9.8%	126.9K	20.3K	—	—
Mueller BrianEVP, Chief Financial Officer · 21 transactions	+169.2%	123.3K	134.1K	—	5.0K
Heron Elaine JDirector · 3 transactions	+10.6%	101.9Kas of Jun 2024	9.8K	—	—
Guyer Charles GregEVP, Chief Technical Officer · 27 transactions	+110.1%	84.1K	133.0K	—	28.8K
Davis George EricEVP, Chief Legal Officer · 26 transactions	+13.1%	78.6K	162.6K	—	107.1K
Ajer Jeffrey RobertEVP, Chief Commercial Officer · 7 transactions	+9.8%	66.8Kas of May 2024	37.5K	—	9.0K
Friberg Gregory REVP, Chief R&D Officer · 9 transactions	—	51.8K	66.4K	—	9.6K
Pyott David E IDirector · 1 transaction	+10.5%	49.8Kas of May 2024	4.7K	—	—
Hombach Robert J.Director · 3 transactions	+61.8%	49.4K	18.9K	—	—
Dere Willard HDirector · 3 transactions	+68.4%	46.4K	18.9K	—	—
Hubbard CristinEVP, Chief Commercial Officer · 10 transactions	—	42.5K	48.5K	—	273
Anderson Elizabeth MDirector · 3 transactions	+81.7%	41.9K	18.9K	—	—
Slamon DennisDirector · 2 transactions	+32.5%	40.8Kas of Mar 2024	10.0K	—	—
Ho MaykinDirector · 3 transactions	+113.3%	35.5K	18.9K	—	—
Ramchandani Rashmi VirendraVP, Chief Accounting Officer · 2 transactions	—	25.6K	25.6K	—	—
Bodem Barbara W.Director · 4 transactions	—	21.0K	21.0K	—	—
Countouriotis AthenaDirector · 4 transactions	—	21.0K	21.0K	—	—
Enyedy Mark JDirector · 4 transactions	—	21.0K	21.0K	—	—
Walbert Timothy PDirector · 3 transactions	—	17.7K	17.3K	—	—
Clark Ian TDirector · 2 transactions	—	14.5K	14.5K	—	—
Burkhart ErinGVP, Chief Accounting Officer · 11 transactions	+0.6%	14.2Kas of May 2025	10.7K	—	7.4K

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.